Ovarian cancer: Etiology, risk factors, and epidemiology

Clinical Obstetrics and Gynecology

Volumn 55, Issue 1, 2012, Pages 3-23

  Hunn, Jessica ^a   Rodriguez, Gustavo C ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

epidemiology; etiology; ovarian cancer; pathogenesis; risk factors

Indexed keywords

ANDROGEN; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; ESTROGEN; GESTAGEN; GONADOTROPIN; PROTEIN P53; TALC;

ARTICLE; BREAST CANCER; BREAST FEEDING; CANCER EPIDEMIOLOGY; CANCER RISK; CARCINOGENESIS; CIGARETTE SMOKING; DNA REPAIR; ENDOMETRIOSIS; EXERCISE; FAMILY HISTORY; FEMALE INFERTILITY; FOOD INTAKE; GEOGRAPHY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MEDICAL HISTORY; MENARCHE; MENOPAUSE; NULLIPARA; OBESITY; ORAL CONTRACEPTION; OVARY CANCER; PELVIC INFLAMMATORY DISEASE; UTERINE TUBE LIGATION;

ANDROGENS; BREAST FEEDING; CONTRACEPTIVES, ORAL, HORMONAL; DIET; ENDOMETRIOSIS; EPITHELIUM; ESTROGENS; EXERCISE; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GEOGRAPHY; GONADOTROPINS; HORMONE REPLACEMENT THERAPY; HUMANS; HYSTERECTOMY; INFLAMMATION; LIFE STYLE; LYNCH SYNDROME II; MUTATION; OBESITY; OVARIAN NEOPLASMS; PARITY; PELVIC INFLAMMATORY DISEASE; PREGNANCY; PROGESTINS; RISK FACTORS; SMOKING; STERILIZATION, TUBAL; TALC;

EID: 84857612237     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e31824b4611     Document Type: Article

References (160)

1. American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011.
2. Brewer MA, Johnson K, Follen M, et al. Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res. 2003; 9:20-30. (Pubitemid 36113233)
3. Rodriguez GC, Walmer DK, Cline M, et al. Effect of progestin on the ovarian epithelium ofMacaques: cancer prevention through apoptosis? J Soc Gynecol Invest. 1998;5:271-276. (Pubitemid 28427517)
4. Rodriguez GC, Nagarsheth NP, Lee KL, et al. Progestin-induced apoptosis in the macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J Natl Cancer Inst. 2002;94:50-60. (Pubitemid 34082843)
5. Scully RE. Pathology of ovarian cancer precursors. J Cell Biochem. 1995;23 (suppl):208-218. (Pubitemid 26032877)
6. Roland IH, Yang WL, Yang DH, et al. Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer. 2003;98: 2607-2623. (Pubitemid 37509524)
7. Yang DH, Smith ER, Cohen C, et al. Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. Cancer. 2002;94:2380-2392. (Pubitemid 34457119)
8. Plaxe SC, Deligdisch L, Dottino PR, et al. Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma. Gynecol Oncol. 1990;38:367-372. (Pubitemid 20362558)
9. Medeiros F, Muto M, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236. (Pubitemid 43740193)
10. Lee Y, Medeiros F, Kindelberger D, et al. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol. 2006;13:1-7. (Pubitemid 44357143)
11. Piek JM, Kenemans P, Verheijen RH, et al. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol. 2004;191:718-732. (Pubitemid 39298100)
12. Medeiros F, Muto M, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236. (Pubitemid 43740193)
13. Crum CP, Drapkin R, Kindelberger D, et al. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007;5: 35-44. (Pubitemid 350218778)
14. Roh MH, Yassin Y, Miron A, Highgrade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol. 2010;23: 1316-1324.
15. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-169. (Pubitemid 46175016)
16. Chivukula M, Niemeier LA, Edwards R, Carcinomas of distal fallopian tube and their association with tubal intraepithelial carcinoma: do they share a common "precursor" lesion? Loss of heterozygosity and immunohistochemical analysis using PAX 2, WT-1, and P53 markers. Obstet Gynecol. 2011; 2011:858647.
17. Shaw PA, Rouzbahman M, Pizer ES, et al. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.Mod Pathol. 2009;22:1133-1138.
18. Schildkraut JM, Bastos E, Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst. 1997;89:932-938. (Pubitemid 27282065)
19. Ames BN, Gold LS. Too many rodent carcinogens: mitogenesis increases mutagenesis. Science. 1990;249:970-971.
20. Preston-Martin S, Pike MC, Ross RK, et al. Increased cell division as a cause of human cancer. Cancer Res. 1990;50: 7415-7421.
21. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136:1212-1220. (Pubitemid 23026892)
22. Anonymous. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med. 1987;316:650-655.
23. Risch HA, Weiss NS, Lyon JL, et al. Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol. 1983;117:128-139. (Pubitemid 13194916)
24. Cramer DW, Hutchinson GB, Welch WR, et al. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst. 1983;71:711-716. (Pubitemid 14232384)
25. Joly DJ, Lilienfeld AM, Diamond EL, et al. An epidemiologic study of the relationship of reproductive experience to cancer of the ovary. Am J Epidemiol. 1974;99:190-209.
26. Hildreth NG, Kelsey JL, LiVolsi VA, et al. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol. 1981;114:398-405. (Pubitemid 11003786)
27. Franceschi S, La Vecchia C, Helmrich SP, et al. Risk factors for epithelial ovarian cancer in Italy. Am J Epidemiol. 1982;115:714-719. (Pubitemid 12074276)
28. Rosenberg L, Shapiro S, Slone D, et al. Epithelial ovarian cancer and combination oral contraceptives. JAMA. 1982; 247:3210-3212. (Pubitemid 12123890)
29. Whittemore AS, Harris R, Itnyre J, et al. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies I. Methods. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136:1175-1183. (Pubitemid 23026889)
30. Fredrickson TN. Ovarian tumors of the hen. Environ Health Perspect. 1987; 73:35-51.
31. Hakim AA, Barry CP, Barnes HJ, et al. Ovarian adenocarcinomas in the laying hen & women have similar alterations in p53, ras, & HER-2/neu. Cancer Prev Res. 2009;2:114-121.
32. MosgaardBJ, LidegaardO,AndersenAN. The impact of parity, infertility and treatment with fertility drugs on the risk of ovarian cancer. Acta Obstel Gynecol Scand. 1997;76:89-95. (Pubitemid 27084708)
33. Cooper GS, Schildkraut JM, Whittemore AS, et al. Pregnancy recency and risk of ovarian cancer. Cancer Causes Control. 1999;10:397-402. (Pubitemid 29454316)
34. Albrektsen G, Heuch I, Kvale G. Reproductive factors and incidence of epithelial ovarian cancer: a Norwegian prospective study. Cancer Causes Control. 1996;7:421-427. (Pubitemid 26228331)
35. Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet. 1994;344: 1250-1254. (Pubitemid 24334680)
36. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 1983;71:717-721. (Pubitemid 14232385)
37. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998; 90:1774-1786. (Pubitemid 28559889)
38. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91: 1459-1467. (Pubitemid 29424550)
39. Shan W, Liu J. Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle. 2009;8: 3107-3111.
40. Cramer DW, BastRC Jr, Berg CD, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res. 2011;4:365-374.
41. Wu ML, Whittemore AS, Paffenbarger RS Jr, et al. Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol. 1988;128:456-466.
42. Coch M, Gaedke H, Jenkins H. Family history of ovarian cancer patients: a case-controlled study. Int J Epidemiol. 1989;18:782-785. (Pubitemid 20030189)
43. Schildkraut JM, Risch N, Thompson WD. Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship. Am J Human Genet. 1989;4:521-529. (Pubitemid 19261439)
44. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer and steroid hormone study. Am J Hum Genet. 1991;48:232-242. (Pubitemid 21891587)
45. Claus EB, Risch N, ThompsonWD.The calculation of breast cancer risk for women with a first-degree family history of ovarian cancer. Breast Cancer Res Treat. 1993;28:115-120. (Pubitemid 24056083)
46. Berchuck A, Cirisano F, Lancaster JM, et al. Role of BRCA1 mutation screening in the management of familial ovarian cancer. Am J Obstet Gynecol. 1996; 175:738-746.
47. Sinilnikova OM, Mazoyer S, Bonnardel C, et al. Gynecologic manifestations of hereditary nonpolyposis colorectal cancer. From inherited to sporadic disease. Fam Cancer. 2006;5:15-20.
48. Sogaard M, Kjaer SK, Gayther S. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention. Acta Obstet Gynecol Scand. 2006;85:93-105. (Pubitemid 43879130)
49. Schwartz MD, Peshkin BN, Tercyak KP, et al. Decision making and decision support for hereditary breast-ovarian cancer susceptibility. Health Psychol. 2005;24 (4, suppl):S78-S84. (Pubitemid 41099129)
50. Nelson HD, Huffman LH, Fu R, et al. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2005;143: 362-379.
51. Taylor N, Mutch DG. Gynecologic manifestations of hereditary nonpolyposis colorectal cancer. From inherited to sporadic disease. Oncology (Huntington). 2006; 20:85-94; discussion 94-96, 100 review. (Pubitemid 46940220)
52. Offit K, Kauff ND. Reducing the risk of gynecologic cancer in the Lynch syndrome. N Engl J Med. 2006;354: 293-295. (Pubitemid 43113037)
53. Schorge JO, et al. SGO White paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol. 2010;119: 7-17.
54. Boyd J, Rubin SC. Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol. 1997;71(2, suppl):517-523.
55. O'Donovan PJ, LivingstonDM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010;31:961.
56. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: result from three U.S. population- based case-control studies of ovarian cancer. Am J Hum Genet. 1997;60: 496-504. (Pubitemid 27097597)
57. Ford D, Easton DP, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62:676-689. (Pubitemid 28164626)
58. Holschneider CH, Berek J. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000; 19:3-10. (Pubitemid 30439309)
59. Antoniou AC, Wang X, Fredericksen ZS, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet. 2010;42: 885-892.
60. Pruthi S, Gostout BS, LindorNM. Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clin Proc. 2010;85: 1111-1120.
61. Lu KH, Broaddus RR. Gynecologic cancers in Lynch syndrome/HNPCC. Fam Cancer. 2005;4:249-254. (Pubitemid 41242195)
62. Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76: 1-18.
63. Lu KH, Dinh M, Kohlmann W, et al. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005;105:569-574. (Pubitemid 40271224)
64. Whiteman DC, Siskind V, Purdie DM, et al. Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:42-46. (Pubitemid 36110156)
65. Rostgaard K, Wohlfahrt J, Andersen PK, et al. Does pregnancy induce the shedding of premalignant ovarian cells? Epidemiology. 2003;14:168-173. (Pubitemid 40417103)
66. Tworoger SS, Fairfield KM, Colditz GA, et al. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol. 2007;166:894-901. (Pubitemid 47511685)
67. Rossing MA, Tang MT, Flagg EW, et al. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol. 2004;160:1070-1078. (Pubitemid 39557459)
68. Jensen A, Sharif H, Frederiksen K, et al. Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study. Br Med J. 2009;338:b249.
69. Mahdavi A, Pejovic T, Nezhat F. Induction of ovulation and ovarian cancer: a critical review of the literature. Fertil Steril. 2006;85:819.
70. Weiss NS, Cook LS, Farrow DC, et al. Ovarian cancer. In: Schottenfeld D, Fraumeni JF Jr. Cancer Epidemiology and Prevention. New York, NY: Oxford University Press; 1996: 1040-1057.
71. Beral V, Doll R, Hermon C, et al. Collaborative Group on Epidemiological Studies of Ovarian CancerOvarian cancer and oral contraceptives: collaborative reanalysis of data from epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303-314.
72. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med. 1998;339:424-428. (Pubitemid 28377683)
73. Danforth KN, Tworoger SS, Hecht JL, et al. Breastfeeding and risk of ovarian cancer in two prospective cohorts. Cancer Causes Control. 2007;18:517-523. (Pubitemid 46684826)
74. Titus-Ernstoff L, Rees JR, Terry KL, et al. Breast-feeding the last born child and risk of ovarian cancer. Cancer Causes Control. 2010;21:201-207.
75. Jordan SJ, Siskind V, Green C. Breastfeeding and risk of epithelial ovarian cancer. Cancer Causes Control. 2010;21: 109-116.
76. Hoekstra A, Rodriguez GC. Chemoprevention of ovarian cancer. Cancer Treat Res. 2009;149:3-34.
77. Choi JH, et al. Gonadotropins and ovarian cancer. Endocr Rev. 2007;28: 440-461.
78. Canman CE, Chen C-Y, Lee MH, et al. Cold Spring Harbor Symposia on Quantitative Biology, LIX DNA Damage Responses: p53 Induction, Cell Cycle Pertubations, and Apoptosis. Woodbury, NY: Cold Spring Harbor Press; 1994: 277-286.
79. Ponzoni M, Bocca P, Chiesa V, et al. Differential effects of N-(4-hydroxyphenyl) retinamide and retrinoic acid on neuroblastoma cells: apoptosis versus differentiation. Can Res. 1995;55: 853-861.
80. Delia D, Aiello A, Lombardi L, et al. N- (4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res. 1993;53: 6036-6041.
81. Lotan R. Retinoids in cancer chemoprevention. FASEB J. 1996;10: 1031-1039. (Pubitemid 26285979)
82. Kuo SM. Antiproliferative potency of structurally distinct dietary flavonoids on human colon cancer cells. Cancer Lett. 1996;110:41-48.
83. Thompson HJ, Jiang C, Lu J, et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 1997;57:420-425.
84. Gould MN. Cancer chemoprevention and therapy by monoterpenes [review] . Environ Health Perspect. 1997;105 (suppl 4):977-979. (Pubitemid 27372991)
85. Pascale RM, Simile MM, De Miglio MR, et al. Chemoprevention by Sadenosyl- L-methionine of rat liver carcinogenesis initiated by 1,2-dimethylhydrazine and promoted by orotic acid. Carcinogenesis. 1995;16:427-430.
86. el-Bayoumy K, Upadhyaya P, Chae YH, et al. Chemoprevention of cancer by organoselenium compounds [review]. J Cell Biochem. 1995;22 (suppl):92-100.
87. Sun SY, Hail N, Lotan R. Apoptosis as a novel target for cancer prevention. J Natl Cancer Inst. 2004;96:662-672. (Pubitemid 38660229)
88. Ouyang N, Williams JL, Rigas B. NOdonating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)delta expression in APC (min/+) mice proportionally to their tumor inhibitory effect: implications for the role of PPARdelta in carcinogenesis. Carcinogenesis. 2006;27: 232-239. (Pubitemid 43159874)
89. Sinicrope FA, Half E, Morris JS, et al. Cell proliferation and apoptotic indices predict adenoma regression in a placebo- controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev. 2004;13:920-927. (Pubitemid 38756701)
90. Vereide AB, Kaino T, Sager G, et al. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol. 2005;97: 740-750. (Pubitemid 40824641)
91. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol. 1999;11:68-75. (Pubitemid 29082059)
92. Schildkraut JM, Calingaert B, March banks PA, et al. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst. 2002;94:32-38. (Pubitemid 34082841)
93. Lacey JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. J Am Med Assoc. 2002;288:334-341. (Pubitemid 34761612)
94. Rodriguez C, Patel AV, Calle EE, et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. J Am Med Assoc. 2001;285:1460-1465. (Pubitemid 32221894)
95. Coughlin SS, Giustozzi A, Smith SJ, et al. A meta-analysis of estrogen replacement therapy and the risk of epithelial ovarian cancer. J Clin Epidemiol. 2000;53:367-375. (Pubitemid 30216475)
96. Garg P, Kerlikowdke K, Subak L, et al. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol. 1998;92: 472-479. (Pubitemid 28396879)
97. Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in 98. Swedish women. J Natl Cancer Inst. 2002;94:497-504. (Pubitemid 34411288)
98. Purdie DM, Bain CJ, Siskind V, et al. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer. 1999;81:559-563. (Pubitemid 29458815)
99. Yang HP, Trabert B, Murphy MA, et al. Ovarian cancer risk factors by histologic subtypes in the NIH-AARP diet and health study. Int J Cancer. 2011. doi: 10.1002/ijc.26469.
100. Modugno F. Ovarian cancer and polymorphisms in the androgen and progesterone receptor genes: a HuGE review. Am J Epidemiol. 2004;159:319-335. (Pubitemid 38200765)
101. Olsen CM, Green AC, Nagle CM, et al. Epithelial ovarian cancer: testing the "androgens hypothesis". Endocr Relat Cancer. 2008;4:1061-1068.
102. Cottreau CM, Ness RB, Modugno F, et al. Endometriosis and its treatment with danazol or lupron in relation to ovarian cancer. Clin Cancer Res. 2003;9: 5142-5144. (Pubitemid 37413563)
103. Greer JB, Modugno F, Allen GO, et al. Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer. Obstet Gynecol. 2005;105: 731-740. (Pubitemid 40432189)
104. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91: 1459-1467. Review. (Pubitemid 29424550)
105. Shan W, Liu J. Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle. 2009;8:3107-3111.
106. McSorley MA, Alberg AJ, Allen DS, et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol. 2007;109:933-941. (Pubitemid 46559083)
107. Toriola AT, Grankvist K, Agborsangaya CB, et al. Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal study. Ann Oncol. 2011;22:1916-1921.
108. Clendenen TV, Lundin E, Zeleniuch- Jacquotte A, et al. Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:799-810.
109. Jensen JT, Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am. 2000;27:705-721.
110. Henderson WJ, Hamilton RC, Griffiths K. Talc in normal and malignant ovarian tissue. Lancet. 1979;1:499.
111. Cramer DW, Welch WR, Scully RE, et al. Ovarian cancer and talc: a casecontrol study. Cancer. 1982;50:372-376. (Pubitemid 12089403)
112. Rosenblatt KA, Szklo M, Rosenshein NB. Mineral fiber exposure and the development of ovarian cancer. Gynecol Oncol. 1992;45:20-25.
113. Chang S, Risch HA. Perineal talc exposure and risk of ovarian carcinoma. Cancer. 1997;79:2396-2401. (Pubitemid 27251024)
114. Harlow BL, Cramer DW, Bell DA, et al. Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol. 1992;80: 19-26.
115. Huncharek M, Geschwind JF, Kupelnick B. Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen observational studies. Anticancer Res. 2003;23: 1955-1960. (Pubitemid 36750874)
116. Sayasneh A, Tsivos D, Crawford R. Endometriosis and ovarian cancer: a systematic review. ISRN Obstet Gynecol. 2011;2011:140310.
117. Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol. 2003;189:280-294. Review. (Pubitemid 36886563)
118. Al-Sabbagh M, Lam EW, Brosens JJ. Mechanisms of endometrial progesterone resistance. Mol Cell Endocrinol. 2011. [Epub ahead of print].
119. Kondi-Pafiti A, Papakonstantinou E, Iavazzo C, et al. Clinicopathological characteristics of ovarian carcinomas associated with endometriosis. Arch GynecolObstet. 2011. [Epub ahead of print].
120. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1995;4:447-451.
121. Lin HW, Tu YY, Lin SY, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a populationbased study. Lancet Oncol. 2011;12: 900-904.
122. Cibula D,Widschwendeter M,Majek O, et al. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update. 2011;17: 55-67.
123. Narod SA, Sun P, Ghadirian P, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet. 2001;357:1467-1470. (Pubitemid 32488854)
124. Dennerstein L, Gotts G, Brown JV. Effects of age and non-hormonal contraception on menstrual cycle characteristics. Gynecol Endocrinol. 1997;11: 127-133. (Pubitemid 27196740)
125. Olsen CM, Green AC, Whiteman DC, et al. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer. 2007;43: 690-709. (Pubitemid 46502901)
126. Calle EE, Rodriguez C, Walker- Thurmond K, et al. Overweight, obesity and mortality from cancer in prospectively studied cohort of US adults. N Engl J Med. 2003;348:1625-1638. (Pubitemid 36459468)
127. Fairfield KM, Willett WC, Rosner BA, et al. Obesity weight gain, and ovarian cancer. Obstet Gynecol. 2002;100:288-296. (Pubitemid 34874792)
128. Purdie DM, Siskind V, Bain CJ, et al. Body size and ovarian cancer: case-control study and systematic review. Cancer Causes Control. 2001;12:855-863. (Pubitemid 33010624)
129. Leitzmann MF, Koebnick C, Danforth KN, et al. Body mass index and risk of ovarian cancer. Cancer. 2009;115: 812-822.
130. McLemore MR, et al. Epidemiologic and genetic factors associated with ovarian cancer. Cancer Nursing. 2009; 32:281-290.
131. LaVecchia C, Decarli A, Franceschis NE, et al. Dietary factors and the risk of epithelial ovarian cancer. J Natl Cancer Inst. 1987;79:663-669. (Pubitemid 17146828)
132. Kushi LH, Mink PJ, Sellers TA, et al. Prospective study of diet and ovarian cancer. Am J Epidemiol. 1999;149: 21-31. (Pubitemid 29028858)
133. Bosetti C, Negri E, Francschi S, et al. Olive oil, seed oils and other added fats in relation to ovarian cancer (Italy). Cancer Causes Control. 2002;13: 465-470. (Pubitemid 34666602)
134. Bosetti C, Negri E, Francschi S, et al. Diet and ovarian cancer risk: a casecontrol study in Italy. Int J Cancer. 2001;93:911-915. (Pubitemid 32756764)
135. Koushik A, Hunter DJ, Spiegelman D, et al. Fruits and vegetables and ovarian cancer risk in a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev. 2005;14:2160-2167. (Pubitemid 41603262)
136. Schulz M, Lahmann PH, Boeing H, et al. Fruit and vegetable consumption and risk of epithelial ovarian cancer: The European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol. 2005;14:2531-2535. (Pubitemid 41752711)
137. Larsson SC, Bergkvist L, Wolk A.Milk and lactose intakes and ovarian cancer risk in the Swedish mammography cohort. Am J Clin Nutr. 2004;80: 1353-1357.
138. Mommers M, Schouten LJ, Goldbohm RA, et al. Dietary consumption and ovarian cancer risk in the Netherlands Cohort Study on Diet and cancer. Br J Cancer. 2006;94:165-170. (Pubitemid 43088559)
139. Chang ET, Lee VS, Canchola AJ, et al. Dietary patterns and risk of ovarian cancer in the California Teachers Study cohort. Nutr Cancer. 2008;60:285-291. (Pubitemid 351601368)
140. Chandran U, Bander EV, Olson SH, et al. Healthy eating index and ovarian cancer risk. Cancer Causes Control. 2011;22:563-571.
141. Bertone ER, Newcomb PA, Willett WC, et al. Recreational physical activity and ovarian cancer in a population-based case-control study. Int J Cancer. 2002; 99:431-436. (Pubitemid 34495859)
142. Tavani A, Gallus S, La Vecchia C, et al. Physical activity and risk of ovarian cancer: an Italian case-control study. Int J Cancer. 2001;91:407-411. (Pubitemid 32049637)
143. Bertone ER, Willett WC, Rosner BA, et al. Prospective study of recreational physical activity and ovarian cancer. J Natl Cancer Inst. 2001;93:942-948. (Pubitemid 32624652)
144. Anderson JP, Ross JA, Folsom AR. Anthropometric variables, physical activity, and incidence of ovarian cancer: The Iowa Women's Health Study. Cancer. 2004;100:1515-1521. (Pubitemid 38366856)
145. Pan SY, Ugnat AM, Mao Y. Physical activity and the risk of ovarian cancer: a case-control study in Canada. Int J Cancer. 2005;117:300-307. (Pubitemid 41377451)
146. Biesma RG, Scouten LJ, Dirx MJ, et al. Physical activity and the risk of ovarian cancer: results from the Netherlands Cohort Study Cancer Causes control. 2006;17:109-115.
147. Tworoger SS, Gertig DM, Gates MA, et al. Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer. 2008;112:1169-1177. (Pubitemid 351304604)
148. Marchbanks PA, Wilson H, Bastos E, et al. Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol. 2000;95:255-260. (Pubitemid 30045650)
149. Kurian AW, Balise RR, McGuire V, et al. Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol. 2005;96: 520-530. (Pubitemid 40127159)
150. Jordan SJ, Whiteman DC, Purdie DM, et al. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol. 2006;103:1122-1129. (Pubitemid 44821349)
151. Goodman MT, Tung KH. Active and passive tobacco smoking and the risk of borderline and invasive ovarian cancer. Cancer Causes Control. 2003;14: 569-577. (Pubitemid 36999971)
152. Zenzes MT, Reed TE, Casper RF. Effect of cigarette smoking and age on the maturation of human oocytes. Hum Reprod. 1997;12:1736-1741. (Pubitemid 27406090)
153. Weshoff C, Gentile F, Lee J, et al. Predictors of ovarian steroid secretion in reproductive age women. Am J Epidemiol. 1996;144:381-388. (Pubitemid 26262201)
154. Khaw K, Tazuke S, Barrett-Connor E. Cigarette smoking and levels of adrenal androgens in postmenopausal women. N Engl J Med. 1988;318:1705-1709.
155. McKinlay SM. The normal menopause transition: an overview. Maturitas. 1996;23:137-145. (Pubitemid 26161855)
156. Garland CF, Mohr SB, Gorham ED, et al. Role of ultraviolet B irradiance and vitamin D in prevention of ovarian cancer. Am J Prev Med. 2006;31:512-514. (Pubitemid 44880583)
157. Lefkowitz ES, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol. 1994;23:1133-1136.
158. Choi KC, et al. The regulation of apoptosis by activin and transforming growth factorbeta in early neoplastic and tumorigenic ovarian surface epithelium. J Clin Endocrinol Metab. 2001;86:2125-2135.
159. Jiang F, Bao J, Li P, et al. Induction of ovarian cancer cell apoptosis by 1,25- dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem. 2004;279:53213-53221. (Pubitemid 40051824)
160. Salazar-Martinez E, et al. Nutritional determinants of epithelial ovarian cancer risk: a case-control study in Mexico. Oncology. 2002;63:151-157.